FHIR © HL7.org  |  Server Home  |  XIG Home  |  XIG Stats  |  Server Source  |  FHIR  

FHIR IG Statistics: PlanDefinition/IMMZD2DTMeaslesOngoingTx

Packagesmart.who.int.immunizations
Resource TypePlanDefinition
IdIMMZD2DTMeaslesOngoingTx
FHIR VersionR4
Sourcehttp://smart.who.int/immunizations/https://build.fhir.org/ig/WorldHealthOrganization/smart-immunizations/PlanDefinition-IMMZD2DTMeaslesOngoingTx.html
URLhttp://smart.who.int/immunizations/PlanDefinition/IMMZD2DTMeaslesOngoingTx
Version0.2.0
Statusdraft
Date2025-07-25T21:56:21+00:00
NameIMMZD2DTMeaslesOngoingTx
TitleIMMZ.D2.DT.Measles Ongoing Transmission
Authoritywho
DescriptionCountries with ongoing transmission in which the risk of measles mortality remains high (countries that provide first dose of measles-containing vaccine (MCV) at 9 months and second dose of MCV at 15 months)

Resources that use this resource

No resources found


Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source

Id: IMMZD2DTMeaslesOngoingTx
Url: IMMZ.D2.DT.Measles Ongoing Transmission
Version: 0.2.0
Title: IMMZ.D2.DT.Measles Ongoing Transmission
Status: draft
Type:

system: http://terminology.hl7.org/CodeSystem/plan-definition-type

code: eca-rule

Date: 2025-07-25 21:56:21+0000
Publisher: WHO
Description:

Countries with ongoing transmission in which the risk of measles mortality remains high (countries that provide first dose of measles-containing vaccine (MCV) at 9 months and second dose of MCV at 15 months)

Knowledge Capability: computable
Related Artifacts:

References

  • WHO recommendations for routine immunization - summary tables (January 2025)


Libraries:
IMMZD2DTMeaslesOngoingTxLogic
Actions:
Determine if the client is due for MCV1 in countries with ongoing transmission.: Determine if the client is due for measles vaccination MCV1 according to the national immunization protocol. Countries with ongoing transmission in which the risk of measles mortality remains high.
If: Applicability: Client is due for MCV1 (Client is due for MCV1)
Then: Definition: IMMZ.D2.DT.Measles.MR
Dynamic Values:
status: ('draft')
intent: ('proposal')
Determine if the client is due for MCV2 in countries with ongoing transmission.: Determine if the client is due for measles vaccination MCV2 according to the national immunization protocol. Countries with ongoing transmission in which the risk of measles mortality remains high.
If: Applicability: Client is due for MCV2 (Client is due for MCV2)
Then: Definition: IMMZ.D2.DT.Measles.MR
Dynamic Values:
status: ('draft')
intent: ('proposal')
Send Guidance for the patient regarding MCV primary series.: Send Guidance for the patient regarding MCV primary series.
If: Applicability: Has Guidance (Has Guidance)
Then: Definition: IMMZ.D2.DT.CR
Dynamic Values:
status: ('active')
payload.contentString: (Guidance)
category.coding: (Code { system: 'http://terminology.hl7.org/CodeSystem/communication-category', code: 'alert' })
priority: (Code { system: 'http://hl7.org/fhir/request-priority', code: 'routine' })

Source

{
  "resourceType": "PlanDefinition",
  "id": "IMMZD2DTMeaslesOngoingTx",
  "meta": {
    "profile": [
      "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-recommendationdefinition",
      "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareableplandefinition",
      "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishableplandefinition"
    ]
  },
  "text": {
    "status": "extensions",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeCapability",
      "valueCode": "computable"
    }
  ],
  "url": "http://smart.who.int/immunizations/PlanDefinition/IMMZD2DTMeaslesOngoingTx",
  "version": "0.2.0",
  "name": "IMMZD2DTMeaslesOngoingTx",
  "title": "IMMZ.D2.DT.Measles Ongoing Transmission",
  "type": {
    "coding": [
      {
        "system": "http://terminology.hl7.org/CodeSystem/plan-definition-type",
        "code": "eca-rule"
      }
    ]
  },
  "status": "draft",
  "experimental": false,
  "date": "2025-07-25T21:56:21+00:00",
  "publisher": "WHO",
  "contact": [
    {
      "name": "WHO",
      "telecom": [
        {
          "system": "url",
          "value": "http://who.int"
        }
      ]
    }
  ],
  "description": "Countries with ongoing transmission in which the risk of measles mortality remains high (countries that provide first dose of measles-containing vaccine (MCV) at 9 months and second dose of MCV at 15 months)",
  "relatedArtifact": [
    {
      "type": "citation",
      "citation": "WHO recommendations for routine immunization - summary tables (January 2025)"
    }
  ],
  "library": [
    "http://smart.who.int/immunizations/Library/IMMZD2DTMeaslesOngoingTxLogic"
  ],
  "action": [
    {
      "extension": [
        {
          "url": "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-rationale",
          "valueMarkdown": "In countries with ongoing transmission in which the risk of measles mortality remains high, MCV1 \n  should be given at 9 months of age. As a general rule, live vaccines should be given either simultaneously or \n  at intervals of 4 weeks. An exception to this rule is oral poliovirus vaccine (OPV), which can be given at any \n  time before or after measles vaccination without interference in the response to either vaccine."
        }
      ],
      "title": "Determine if the client is due for MCV1 in countries with ongoing transmission.",
      "description": "Determine if the client is due for measles vaccination MCV1 according to the national immunization protocol.\nCountries with ongoing transmission in which the risk of measles mortality remains high.",
      "condition": [
        {
          "kind": "applicability",
          "expression": {
            "description": "Client is due for MCV1",
            "language": "text/cql-identifier",
            "expression": "Client is due for MCV1"
          }
        }
      ],
      "definitionCanonical": "http://smart.who.int/immunizations/ActivityDefinition/IMMZD2DTMeaslesMR",
      "dynamicValue": [
        {
          "path": "status",
          "expression": {
            "language": "text/cql-expression",
            "expression": "'draft'"
          }
        },
        {
          "path": "intent",
          "expression": {
            "language": "text/cql-expression",
            "expression": "'proposal'"
          }
        }
      ]
    },
    {
      "extension": [
        {
          "url": "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-rationale",
          "valueMarkdown": "In countries with ongoing transmission in which the risk of measles mortality remains high, MCV2 \nshould be given at 15–18 months. The minimum interval between MCV1 and MCV2 is 4 weeks. As a general rule, \nlive vaccines should be given either simultaneously or at intervals of 4 weeks. An exception to this rule is \nOPV, which can be given at any time before or after measles vaccination without interference in the response \nto either vaccine."
        }
      ],
      "title": "Determine if the client is due for MCV2 in countries with ongoing transmission.",
      "description": "Determine if the client is due for measles vaccination MCV2 according to the national immunization protocol.\nCountries with ongoing transmission in which the risk of measles mortality remains high.",
      "condition": [
        {
          "kind": "applicability",
          "expression": {
            "description": "Client is due for MCV2",
            "language": "text/cql-identifier",
            "expression": "Client is due for MCV2"
          }
        }
      ],
      "definitionCanonical": "http://smart.who.int/immunizations/ActivityDefinition/IMMZD2DTMeaslesMR",
      "dynamicValue": [
        {
          "path": "status",
          "expression": {
            "language": "text/cql-expression",
            "expression": "'draft'"
          }
        },
        {
          "path": "intent",
          "expression": {
            "language": "text/cql-expression",
            "expression": "'proposal'"
          }
        }
      ]
    },
    {
      "title": "Send Guidance for the patient regarding MCV primary series.",
      "description": "Send Guidance for the patient regarding MCV primary series.",
      "condition": [
        {
          "kind": "applicability",
          "expression": {
            "description": "Has Guidance",
            "language": "text/cql-identifier",
            "expression": "Has Guidance"
          }
        }
      ],
      "definitionCanonical": "http://smart.who.int/immunizations/ActivityDefinition/IMMZD2DTCR",
      "dynamicValue": [
        {
          "path": "status",
          "expression": {
            "language": "text/cql-expression",
            "expression": "'active'"
          }
        },
        {
          "path": "payload.contentString",
          "expression": {
            "language": "text/cql-identifier",
            "expression": "Guidance"
          }
        },
        {
          "path": "category.coding",
          "expression": {
            "description": "Category of communication",
            "language": "text/cql-expression",
            "expression": "Code { system: 'http://terminology.hl7.org/CodeSystem/communication-category', code: 'alert' }"
          }
        },
        {
          "path": "priority",
          "expression": {
            "description": "Alert priority",
            "language": "text/cql-expression",
            "expression": "Code { system: 'http://hl7.org/fhir/request-priority', code: 'routine' }"
          }
        }
      ]
    }
  ]
}